Delphia (USA)’s Immunovant IMVT Stock Holding History

Delphia (USA)’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13,713	Closed	-$76K	–	437
2022 Q1	$76K	Sell	13,713 -49	-0.4%	-$305	0.06%	313
2021 Q4	$117K	Buy	+13,762	New	+$114K	0.12%	246

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Delphia (USA)'s IMVT Position: Q2 2022 in Review

Delphia (USA) sold out of Immunovant (IMVT) in Q2 2022, closing a stake of 13,713 shares — an estimated $76K sold.

Delphia (USA) first reported a position in IMVT in Q4 2021 and held it in 2 quarters. The position peaked at $117K in Q4 2021. 94 funds tracked by Wall St. Rank hold IMVT as of Q2 2022.

Delphia (USA) reported no remaining Immunovant position as of Q2 2022 after selling out during the quarter.
Delphia (USA) sold 13,713 Immunovant shares in Q2 2022, an estimated $76K.
Delphia (USA) first reported a position in Immunovant in Q4 2021 and held it in 2 quarters.
Delphia (USA)'s Immunovant position peaked at $117K in Q4 2021.
94 funds tracked by Wall St. Rank held Immunovant as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.